One of the most important challenges facing modern preventative medicine is the problem of how best to identify and treat those at highest risk of developing cardiovascular disease, for whom appropriate management (ranging from lifestyle modification to therapeutic regimens) can improve both duration and quality of life. The use of risk assessment can contribute greatly to identifying those individuals who will benefit from riskreducing interventions. However, assessment tools
Introduction
Despite recent encouraging trends that have shown progressive decreases in cardiovascular mortality in North America, Western Europe, Japan and Australasia, 1 coronary heart disease (CHD) remains the principal cause of death in industrialised Western societies. 2 In the UK, CHD claims 150 000 lives annually, of which half may be regarded as premature, 3 while, each year in the USA, cardiovascular disease (CVD) contributes more than 500 000 strokes and 1.25 million coronary events. 4, 5 In addition, the management of non-fatal CVD consumes large proportions of the health care budget in hospital admissions and aftercare and also causes considerable personal distress and disability. These continuing costs are disappointing in view of the fact that much CVD is preventable.
Nearly half a century of epidemiological investigation and randomised controlled trials have shown that there are significant components of CVD that can be reduced, or eliminated, by lifestyle modifications 6 and therapeutic interventions. For example, treatment of hypertension or of hypercholesterolaemia has been shown to reduce cardiovascular morbidity and mortality. [7] [8] [9] One of the most important challenges facing modern preventive medicine is, therefore, the problem of how best to identify those at highest risk of developing CVD, for whom appropriate management (ranging from lifestyle modification to therapeutic regimens) can improve both the duration and the quality of life. These requirements have encouraged the development of guidelines for the characterisation of patients according to the likelihood, or risk, of CVD. 
Identification of risk factors
The identification of factors involved in determining the risk of developing CVD marked a major advance in the organisation of a systematic approach to preventing these conditions. By identifying risk factors and quantifying risk, the need for therapeutic intervention can be determined as can the type of intervention most appropriate for lowering individual risk of developing CVD and the most cost-effective regimen for the management of patients who have developed CVD. 10 In addition to providing goals and targets for therapeutic interventions, risk factor assessment assists in motivating both patients and health care teams, by enabling changes in the patient's condition to be monitored and thereby reinforcing improvement. Guidelines on cardiovascular risk and its management provide the general public with information about the factors that predispose to cardiovascular risk as well as promoting awareness of the patient's own personal risk of developing CVD. Patients assessed as having low risk can be reassured and those with higher risks can be counselled to adopt risk-reducing lifestyle changes such as stopping smoking, dietary modifications, increasing exercise and reducing weight. 11 Guidelines on lifestyle changes that reduce the risk of CVD can also assist health care professionals in educating the public.
Some early guidelines took a unifactorial approach to the risk of developing CVD and based recommendations for assessment and treatment purely on the levels of isolated risk factors such as serum cholesterol or blood pressure (BP). However, it is clear that, in Western populations, CVD has multiple determinants that interact in an adverse manner resulting in a cumulative impact on the risk of developing CVD. Hence a multifactorial approach, which takes into account several risk fac-tors, and which may involve multiple intervention regimens, is probably the best strategy for the prevention of CVD. 12 The Framingham Heart Study is one of the most important epidemiological studies of cardiovascular risk factors. This study recruited more than 7000 men and women aged 30-62 living in Framingham, Massachusetts, USA, in the 1960s and followed these individuals and their offspring biennially until the present. This study has played a vital role in defining the contribution of various risk factors to CHD in a US population.
The factors that have been shown to be causally related to an increased risk of CVD have included high BP, cigarette smoking, elevated blood levels of total and low-density lipoprotein (LDL) cholesterol, low concentrations of high-density lipoprotein (HDL) cholesterol, and diabetes ( Figure 1 ). [13] [14] [15] Although the precise mechanisms whereby these six factors promote atherosclerosis and predispose to CVD are not fully understood, abundant evidence supports a direct causal role. These factors produce adverse effects on the development of CHD independently of one another 12 and are referred to as 'major risk factors' because they occur commonly, and act powerfully, in societies that have high rates of CHD.
Additional risk factors include elevated concentrations of serum triglycerides, lipoprotein A, small dense LDL particles, homocysteine and coagulation factors. These factors are clearly associated with an increased risk of CHD but their causal link to CHD is perhaps not as robust as for the major risk factors.
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Other factors such as male gender, obesity, lack of physical exercise, and a family history of premature CHD are also associated with increased CHD risk and have therefore been considered in defining CHD Kannel, 1987 , with permission from Excerpta Medica Inc. 13 risk, 16 as have advanced age and left ventricular hypertrophy (LVH). 17 These factors might be considered to be predisposing factors rather than major causal factors. The association between predisposing factors and the development of CHD is complex, but it seems likely that their actions are mediated, at least in part, through causal factors.

Calculation of cardiovascular risk
Even when a complete clinical picture covering all relevant information is available, physicians do not usually predict risk accurately. For example, in a French study, 18 six hypertension specialists were asked to assign 100 patients to the categories of low, moderate or high risk. The proportions of patients assigned by the physicians to each category ranged from 23 to 77% for the low-risk and from 4.5 to 44% for the high-risk group. Bias and lack of reproducibility influenced physicians' judgement in assessing the CVD risk of hypertensive patients. The authors concluded that application of computer aids could result in more rational assessment and better decision making.
The most widely-used quantitative method of cardiovascular risk assessment has been the Framingham equation, developed for predicting the risks of myocardial infarction (MI), CHD, death from CHD, stroke, CVD and death from CVD. 17 The absolute risk of CVD is calculated using eight clinical and biochemical variables (age, gender, smoking history, diabetes mellitus, systolic (SBP) or diastolic BP (DBP), presence or absence of LVH, and concentrations of total and HDL-cholesterol). By using the equation, absolute risk is estimated in terms of percentage likelihood.
Since the equation is complex, the Framingham Heart Study has developed an adjusted scoring system. This scoring system assigns scores (points) to the factors of age, concentrations of total and HDL cholesterol, BP, concentrations of fasting plasma glucose and whether or not the patient is a smoker. The points are added and the total corresponds to an aggregate value for absolute risk (%).
17,19
Limitations of the Framingham study for assessing cardiovascular risk
It has been pointed out that the Framingham system does not assign quantitative scores to several risk factors 12 and factors such as obesity, physical inactivity and a family history of premature CVD are not included.
Concerns have also been raised that because the Framingham cohort is predominantly Caucasian and largely middle class, the data are not generalisable. However, the use of Framingham scores is probably valid in various US ethnic groups 20 and in predominantly Caucasian populations in Northern Europe 21 and in Western Australia, 22, 23 although in the latter setting stroke prediction was unsatisfactory.
Furthermore, the Framingham projections may underestimate the risk of CVD in South Asians living in the USA and elsewhere.
Within the Framingham database individuals S13 with diabetes and more severe hypertension were relatively scarce. Thus, the derived calculation is probably more reliable for individuals with fewer, milder risk factors. 17 Whatever its limitations, the Framingham study has formed the basis for several risk assessment guidelines including the New Zealand system, 24, 25 the Joint British recommendations on prevention of CHD in clinical practice 26 and the British Hypertension Society Guidelines 27 as well as contributing to the reports of the most recent national guidelines on the detection, evaluation and treatment of high BP 28 and cholesterol 16 in the USA. The Framingham risk equation has also been endorsed by the UK Standing Medical Advisory Committee (SMAC) 29 and used to produce the Sheffield tables. 30 A laboratory-based computer programme has been developed in the UK based on the Framingham study for use in a diabetic clinic, 31 and the Joint British recommendations also included a computerised 'Cardiac Risk Assessor' also based on the Framingham study.
In addition, a computer system for CVD risk assessment has been devised by Hingorani and Vallance. 32 The programme utilises the full Framingham equation (rather than the approximation that is used in the production of some charts) and results in displays of absolute and relative risk. This programme has the advantage that it can be used to more accurately quantify the maximal benefit that can be derived from modifying risk factors.
Other CVD risk assessment tools have also been developed. For example, risk assessment has been investigated by the Prospective Cardiovascular Munster Heart Study (PROCAM), 33, 34 which followed-up nearly 5000 men aged between 40 and 65 years for at least 8 years. Using multivariate analysis, this study confirmed that increased age, increased LDL-cholesterol levels, decreased HDLcholesterol levels, increased BP, cigarette smoking, diabetes mellitus and family history of CVD are important risk factors for MI or cardiac death. Interestingly, the Munster study also demonstrated elevated triglycerides to be an independent risk factor. These analyses provided the basis for the development of an algorithm for the assessment of the individual risk of MI. However, this study can be criticised for using data obtained exclusively in men and extrapolating to women.
One of the first systems for assessing and grading modifiable risk in the UK was developed in Dundee. 35 This system assessed risk on a scale of 1 (high risk) to 100 (low risk) according to age and gender based on smoking, BP and cholesterol levels. The data are entered onto a disc that is not easy to use and includes too few risk factors.
The NCEP 16 and the National High Blood Pressure Education Program's Joint National Committee 28 recommend the counting of categorical risk factors as the first step in clinical risk assessment. However, the allocation of definitive cut-off points for BP or serum cholesterol levels has been criticised as arbitary, 36 especially as there is a continuous linear relationship between BP and incidence of stroke or heart attack 37 ( Figure 2 ) and between serum choles-
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terol and risk of CHD. Indeed, it has been emphasised that most CHD events and strokes occur in individuals with apparently 'normal' BP. 38 Other groups have, therefore, taken the view that more precision is needed for evaluating absolute risk assessment and that continuous variables should be used rather than categorical values. Thus, most recent guidelines use charts that allow actual BP readings and lipid ratios to be used in making assessments for the prediction of coronary risk.
Relative and absolute risk
Absolute risk is the probability expressed for example as a percentage of developing a condition such as CHD within a finite period (eg within the next 10 years). Relative risk is the ratio of the likelihood of a condition developing in a person with a given aetiological factor compared with the likelihood of that condition developing in an individual (usually matched for age and gender), but without that factor. Young people with CVD risk factors are rarely at a high absolute risk of CVD in the short term, but in comparison with their healthy peer group, they will have a high relative risk of CVD. Furthermore a 35-year-old woman with 'normal' BP would be expected to live until age 76. With only a slight increase in BP, to 140/95 mm Hg (a level that would not require treatment in most assessment systems and associated with a low short-term absolute risk) life expectancy would be 60 years -a reduction of 16 years. Such an individual is unlikely to gain immediate benefits from treatment, and may therefore not be prescribed treatment, but is likely to benefit from risk-reducing interventions in the long term. Conversely, every elderly person (of about 80 years) will have an absolute risk that warrants treatment, according to most guidelines, even though their risk relative to their peers may be only marginally increased. These examples highlight the problem common to all risk assessment guidelines, namely that older patients may tend to be overtreated and younger patients, who would benefit long term from early intervention, are not included in the recommended treatment groups based on estimated short-term absolute risk. The use of shortterm absolute risk to determine therapy therefore requires review and modification. 39 One approach when dealing with younger patients at high relative but low absolute risk is to evaluate risk levels as if the patient was 60 years of age and treat on that basis.
Attributable risk is the difference in absolute risk between individuals with and without a given risk factor. It therefore provides an estimate of the 'excess (absolute) risk' attributable to a given risk factor. Because absolute risk is usually low in the young, so too is attributable risk and, like absolute risk, it increases with age. 40 
Diabetic patients
Using coefficients derived from the Framingham study and a meta-analysis of the influence of microalbuminaemia on the risk of CVD, Yudkin and Chaturvedi 41 have derived charts for 10-year risk assessment of CVD in diabetic males and females. These risk estimates were validated by comparison with the Dundee Risk Disk and the PROCAM study. The American Heart Association has also produced guidelines specifically tailored to diabetic patients based on the Framingham data. 42 However, in the light of prospective data, which showed diabetic patients to have mortality rates similar to those of non-diabetics who have had an MI, 43 it has been reasonably proposed that patients with diabetes could and perhaps should be considered as for secondary prevention and hence risk assessment is less critical.
Using risk assessment guidelines
The pathway to reduction of risk involves three steps: 44 (1) the identification and measurement of risk factors and collection of clinical data relevant for assessing patient risk; (2) the interpretation of risk-related data with estimation of risk in absolute, as well as in relative terms; (3) the use of therapeutic intervention to minimise disease risk or to prevent the development of risk factors.
Although this algorithm seems reasonably straightforward, in practice problems arise with each step. Several studies have shown that clinicians often fail to collect routinely even basic information such as plasma cholesterol, BP and cigarette smoking status during the course of medical care. 45 On the other hand, a policy of proactive invitation to patients for assessment of cardiovascular risk factors corresponded with higher recording levels in general practice. 46 The inherent weaknesses of assessment tools have been discussed above.
The lack of uniformity among guidelines has been illustrated by a study that compared risk assessment methods and criteria used for deciding whether to prescribe lipid-lowering medication. Durrington and colleagues 47 compared the algorithms, charts and tables used by the US NCEP, 16 the joint guidelines of the European Society of Cardiology, the European Atherosclerosis Society and the European Society of Hypertension, 48 and the report of the UK SMAC NHS Executive 29 with the Framingham risk equation 11 programmed into a computer. In those patients in whom the NCEP and UK guidelines could be compared, 52% of the men and 72% of the women met NCEP criteria for requiring lipid-lowering medication, whereas only 9% of the men and less than 1% of the women met the UK criteria. The Framingham equation estimated a CHD risk of more than 3% per year in 22% of the men and 7% of the women, indicating that the UK tables underestimated CHD risk. European guidelines could be applied to only two-thirds of the patients and were reasonably accurate in the assessment of a CHD risk of 2% per year. It seems that a large number of patients who are at high risk of CHD are not eligible for statin treatment based on some assessment methods 47 because not all of the critical risk factors have been considered.
The final step to effective risk reduction involves appropriate therapeutic intervention. However, survey data show that physicians frequently fail to follow treatment thresholds or achieve target levels for optimal risk reduction. 49, 50 Problems with patient compliance and inadequate follow-up contribute to the inadequate risk factor control, but the physician must shoulder the blame for most of the inertia.
Conclusion
The use of risk assessment can contribute greatly to management of CVD by identifying those individuals who, while not symptomatic, will potentially benefit from risk-reducing interventions. However, assessment tools must always be used with care, because some are not sufficiently accurate, while S15 most systems are subject to ageist bias because they are not constructed to take into account the benefits of long-term treatment or risk. Nonetheless, the assessment techniques can provide a more logical approach to patient management, can predict shortterm benefits, and can provide accurate data to substantiate a physician's clinical judgement. The current move towards computerised analytical systems, which take into account a large number of risk factors promises to greatly improve the accuracy and convenience of risk assessment and management.
